Platinum

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Platinum
Accession Number
DB12257
Description

Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 195.084
Monoisotopic: 194.964774449
Chemical Formula
Pt
Synonyms
  • platino

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CabazitaxelThe risk or severity of adverse effects can be increased when Platinum is combined with Cabazitaxel.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Platinum.
DocetaxelThe risk or severity of adverse effects can be increased when Platinum is combined with Docetaxel.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Platinum.
FosphenytoinPlatinum can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Platinum.
PaclitaxelThe risk or severity of adverse effects can be increased when Platinum is combined with Paclitaxel.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Platinum.
PhenytoinPlatinum can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
TopotecanThe risk or severity of adverse effects can be increased when Platinum is combined with Topotecan.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous transition metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous transition metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous transition metal
Molecular Framework
Not Available
External Descriptors
elemental platinum (CHEBI:33400)

Chemical Identifiers

UNII
49DFR088MY
CAS number
7440-06-4
InChI Key
BASFCYQUMIYNBI-UHFFFAOYSA-N
InChI
InChI=1S/Pt
IUPAC Name
platinum
SMILES
[Pt]

References

General References
Not Available
Human Metabolome Database
HMDB0013671
PubChem Compound
23939
PubChem Substance
347828531
ChemSpider
22381
RxNav
1311280
ChEBI
33364
PharmGKB
PA150595617
Wikipedia
Platinum

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
4Unknown StatusTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingPreventionNon-Small Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentAdvanced Urothelial Carcinoma / Metastatic Bladder Urothelial Carcinoma / Metastatic Hormone Refractory Prostate Cancer / Metastatic Renal Pelvis Urothelial Carcinoma / Metastatic Ureter Urothelial Carcinoma / Metastatic Urethral Urothelial Carcinoma / Stage IV Bladder Urothelial Carcinoma AJCC v7 / Stage IV Prostate Cancer AJCC v7 / Stage IV Renal Pelvis Cancer AJCC v7 / Stage IV Ureter Cancer AJCC v7 / Stage IV Urethral Cancer AJCC v7 / Unresectable Urothelial Carcinoma / Urothelial carcinoma ureter metastatic1
3Active Not RecruitingTreatmentAnaplastic Ependymoma / Brain Ependymoma / Cellular Ependymoma / Clear Cell Ependymoma / Ependymomas / Papillary Ependymoma1
3Active Not RecruitingTreatmentAnaplastic Medulloblastoma / Medulloblastomas1
3Active Not RecruitingTreatmentAnticancer Treatment1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage IA Uterine Corpus Cancer AJCC v7 / Stage IB Uterine Corpus Cancer AJCC v7 / Stage II Uterine Corpus Cancer AJCC v7 / Stage IIIA Uterine Corpus Cancer AJCC v7 / Stage IIIB Uterine Corpus Cancer AJCC v7 / Stage IIIC Uterine Corpus Cancer AJCC v7 / Stage IVA Uterine Corpus Cancer AJCC v71
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.03ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:44 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates